Stockscreener 앱 받기
0.4247
27.83%
-0.1633
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
IceCure prices $4M direct offering, concurrent private placement - MSN
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire
[Form 3] IceCure Medical Ltd. Initial S... - Stock Titan
Huang Yang reports RSUs and options in IceCure Medical (NASDAQ: ICCM) - Stock Titan
IceCure Medical (NASDAQ: ICCM) director Chan Vincent Chun Hung files Form 3 - Stock Titan
IceCure Medical (ICCM) VP discloses shares, RSUs and option grants - Stock Titan
IceCure Medical (ICCM) COO discloses share, option and RSU stakes - Stock Titan
IceCure Medical (ICCM) VP details RSUs and stock option grants - Stock Titan
IceCure Medical (ICCM) CFO details shares, RSUs and options in Form 3 - Stock Titan
IceCure Medical (ICCM) director discloses shares and options in Form 3 - Stock Titan
IceCure Medical (ICCM) VP Naum Muchnik details insider share and option holdings - Stock Titan
IceCure Medical (ICCM) VP details share, option and RSU holdings - Stock Titan
IceCure Medical (ICCM) CEO details share, RSU and option stakes - Stock Titan
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates - Bitget
IceCure Medical Posts Strong 5-Year Kidney Cancer Cryoablation Data From ICESECRET Trial - TipRanks
IceCure Medical Ltd Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study - marketscreener.com
IceCure Medical (ICCM) Reports Positive Outcomes in Kidney Cance - GuruFocus
IceCure Medical (Nasdaq: ICCM) unveils 5-year kidney cancer data - Stock Titan
IceCure names Meir Peleg as CFO - Medical Buyer
[EFFECT] IceCure Medical Ltd. SEC Filing - Stock Titan
IceCure Medical Names New CFO and Plans Key Leadership Changes Amid ProSense® Growth - TipRanks
IceCure Medical (NASDAQ: ICCM) hires Meir Peleg as new CFO - Stock Titan
IceCure Medical Ltd. Appoints Meir Peleg as Chief Financial Officer, Effective May 17, 2026 - marketscreener.com
[EFFECT] IceCure Medical Ltd.... | ICCM SEC FilingForm EFFECT - Stock Titan
Dip Buying: Is IceCure Medical Ltd subject to activist investor interest2026 Selloffs & Precise Buy Zone Identification - baoquankhu1.vn
Published on: 2026-03-22 01:37:56 - baoquankhu1.vn
Icecure Medical Ltd (ICCM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic U.S. ... By GuruFocus - Investing.com Canada
Ideas Watch: What dividend growth rate does IceCure Medical Ltd offerM&A Rumor & Breakout Confirmation Trade Signals - baoquankhu1.vn
Icecure Medical Ltd (ICCM) Q4 2025 Earnings Call Highlights: Rec - GuruFocus
IceCure Medical (NASDAQ: ICCM) registers $100M shelf for shares and warrants - Stock Titan
IceCure Medical (NASDAQ: ICCM) registers 9.74M shares from outstanding warrants - Stock Titan
History Review: Is IceCure Medical Ltd stock a good dividend stock2026 Volume & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
ICCM SEC FilingsIcecure Medical Ltd. 10-K, 10-Q, 8-K Forms - Stock Titan
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2025 earnings call transcript - MSN
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2025 Earnings Call Transcript - Insider Monkey
IceCure reports net loss of USD 15,057,000 in 2025 - Medical Buyer
Icecure Medical Rides FDA, ASBRS Wins to Growth - TipRanks
IceCure Medical Discloses Resignation of Director Li Haixiang - TipRanks
IceCure Medical (ICCM) director Li Haixiang steps down from board - Stock Titan
IceCure Medical (ICCM) Q4 2025 Earnings Transcript - AOL.com
IceCure Medical Ltd Announces Resignation of Li Haixiang as Member of the Board of Directors, Effective March 17, 2026 - marketscreener.com
IceCure Medical 2025 Financial Results Review | ProSense System UpdatesNews and Statistics - IndexBox
IceCure Medical (ICCM) Fourth Quarter 2025 Earnings Call Transcript - Bitget
IceCure Medical Ltd Q4 2025 Earnings Call Summary - Yahoo Finance
ICCM: Record revenue and regulatory milestones drive rapid adoption and expansion for ProSense - TradingView
ICCM: Record revenue and regulatory milestones fuel rapid adoption and growth outlook for ProSense - TradingView
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ICCM Reports Record FY25 Revenue Growth Following Key FDA Cleara - GuruFocus
IceCure Reports 2025 Full Year Financial & Operational Results - GuruFocus
IceCure Medical Posts Record 2025 Sales as ProSense Cryoablation Adoption Accelerates Post-FDA Clearance - TipRanks
Icecure Medical Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
IceCure Medical (Nasdaq: ICCM) posts record 2025 revenue but $15.1M loss - Stock Titan
IceCure Medical (NASDAQ: ICCM) 20-F details going concern risk and FDA breast cancer OK - Stock Titan
IceCure's breast tumor freezing tech sets sales record, eyes 7,130 patients - Stock Titan
IceCure Medical Q4 2025 Earnings Call Transcript - MarketBeat
Hedge Fund Bets: Is IceCure Medical Ltd forming a breakout pattern2026 Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
IceCure (ICCM) updates auditor consent in Form F-3/A shelf amendment - Stock Titan
What To Expect From Icecure Medical Ltd (ICCM) Q4 2025 Earnings - GuruFocus
IceCure Medical Ltd Auditor Raises 'Going Concern' Doubt - marketscreener.com
IceCure Medical : Company Presentation - marketscreener.com
New Highs: Is IceCure Medical Ltd subject to activist investor interest2026 Trade Ideas & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Icecure Medical Ltd expected to post a loss of 4 cents a shareEarnings Preview - TradingView
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense Cryoablation in the Local Treatment of Low-Risk Breast Cancer - Finviz
FDA Greenlights IceCure’s ProSense® Study for Breast Cancer - Zenopa
0.00%
0.00%
자본화:
|
볼륨(24시간):